Cargando…

Interleukin-6: a potent biomarker of mycobacterial infection

BACKGROUND: Human tuberculosis (TB), a chronic inflammatory disease is caused by Mycobacterium tuberculosis, a facultative intramacrophage pathogen. The highly complex interactions between mycobacteria and macrophages (MΦs), characterized in part by the induction and elaboration of several cytokines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Prati Pal, Goyal, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893321/ https://www.ncbi.nlm.nih.gov/pubmed/24455461 http://dx.doi.org/10.1186/2193-1801-2-686

Ejemplares similares

Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460
por: Jhamb, Sarbjit Singh, et al.
Publicado: (2014)

Biomarker Discovery in Subclinical Mycobacterial Infections of Cattle
por: Seth, Meetu, et al.
Publicado: (2009)

Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection
por: Heyckendorf, Jan, et al.
Publicado: (2015)

Decavanadate Inhibits Mycobacterial Growth More Potently Than Other Oxovanadates
por: Samart, Nuttaporn, et al.
Publicado: (2018)

Hemophagocytic lymphohistiocytosis complicating nontuberculous mycobacterial infection
por: Gupta, Stuti, et al.
Publicado: (2019)

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo
por: Ranganath, Sheila, et al.
Publicado: (2015)

Ursolic Acid and Solasodine as Potent Anti-Mycobacterial Agents for Combating Paratuberculosis: An Anti-Inflammatory and In Silico Analysis
por: Navabharath, Manthena, et al.
Publicado: (2022)

Sternal mycobacterial infections
por: Yuan, Shi-Min
Publicado: (2016)

Mycobacterial skin infection
por: Gardini, Giulia, et al.
Publicado: (2022)

Sensing of mycobacterial arabinogalactan by galectin‐9 exacerbates mycobacterial infection
por: Wu, Xiangyang, et al.
Publicado: (2021)

Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development
por: Siewko, Katarzyna, et al.
Publicado: (2019)

Mycobacterial infection induces higher interleukin-1β and dysregulated lung inflammation in mice with defective leukocyte NADPH oxidase
por: Chao, Wen-Cheng, et al.
Publicado: (2017)

Decreased Interleukin-1 Family Cytokine Production in Patients with Nontuberculous Mycobacterial Lung Disease
por: Jung, Bock-Gie, et al.
Publicado: (2022)

Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging
por: Blanc, Landry, et al.
Publicado: (2018)

Alginate-Capped Silver Nanoparticles as a Potent Anti-mycobacterial Agent Against Mycobacterium tuberculosis
por: Chen, Cheng-Cheung, et al.
Publicado: (2021)

An atypical mycobacterial infection of the shoulder
por: Talbot, Christopher L., et al.
Publicado: (2012)

Interleukin-6 as a Prognostic Biomarker in Ruptured Intracranial Aneurysms
por: Kao, Hung-Wen, et al.
Publicado: (2015)

The extracellular matrix of mycobacterial biofilms: could we shorten the treatment of mycobacterial infections?
por: Chakraborty, Poushali, et al.
Publicado: (2019)

Discovery of Nosiheptide, Griseoviridin, and Etamycin as Potent Anti-Mycobacterial Agents against Mycobacterium avium Complex
por: Hosoda, Kanji, et al.
Publicado: (2019)

Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis
por: Tran, Anh T., et al.
Publicado: (2017)

Interleukin-6 as A Prognostic Biomarker in Perinatal Asphyxia
por: BOSKABADI, Hassan, et al.
Publicado: (2021)

Interleukin 6: A biomarker for COVID-19 progression
por: Sebbar, El-houcine, et al.
Publicado: (2023)

A Clear View of Mycobacterial Infection
Publicado: (2004)

Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha
Publicado: (1995)

N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions
por: Amaral, Eduardo P., et al.
Publicado: (2016)

Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease
por: Cowman, Steven A., et al.
Publicado: (2018)

High Secretion of Interleukin-6 and Increased MINCLE Receptor Expression Upon Exposure to Mycobacterial Cord Factor Analog Trehalose-6, 6-Dibehenate (TDB) in Patients with Takayasu Arteritis
por: Gupta, Nikhil, et al.
Publicado: (2018)

Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients
por: Othman, Mohamed S., et al.
Publicado: (2013)

Current understanding on micro RNAs and its regulation in response to Mycobacterial infections
por: Singh, Pravin Kumar, et al.
Publicado: (2013)

Interleukin-8 and Interleukin-6 Are Biomarkers of Poor Prognosis in Esophageal Squamous Cell Carcinoma
por: Pastrez, Paula Roberta Aguiar, et al.
Publicado: (2023)

Innate Immune Effectors in Mycobacterial Infection
por: Saiga, Hiroyuki, et al.
Publicado: (2011)

The Role of Nitric Oxide in Mycobacterial Infections
por: Yang, Chul-Su, et al.
Publicado: (2009)

Clofazimine for Rapidly Growing Mycobacterial Infections
por: Carey, George B, et al.
Publicado: (2017)

The Role of NRF2 in Mycobacterial Infection
por: Matsuyama, Masashi, et al.
Publicado: (2021)

Cellular and Molecular Mechanisms in Mycobacterial Infection
por: Nieuwenhuizen, Natalie E., et al.
Publicado: (2022)

Mycobacterial Dormancy Regulon Protein Rv2623 as a Novel Biomarker for the Diagnosis of Latent and Active Tuberculous Meningitis
por: Jain, Ruchika K., et al.
Publicado: (2013)

Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection
por: Paquette, Stéphane G., et al.
Publicado: (2012)

Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds
por: Anagani, B., et al.
Publicado: (2020)

Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis
por: Xia, Qianjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hlp2fi6to5kgs8rn26a2t04i4h